Mylan And Pfizer Announce Key Date For Viatris Merger
Follows Delay Due To Coronavirus Pandemic
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.
You may also be interested in...
Another regulatory approval for Mylan and Upjohn’s proposed combination into Viatris has been ticked off, with the Australian Competition and Consumer Commission saying it will not oppose the deal after Upjohn agreed to divestments to Aspen Pharmacare.
Drawing on the company’s Latin name, Viatris – the proposed combination of Mylan and Upjohn – has unveiled a logo and branding “capturing the company’s commitment to access, leadership and partnership.”
Mylan and Upjohn are aiming to combine into Viatris by the end of 2020, together ticking off regulatory and financial milestones since the deal was announced in late July last year. Mylan shareholder approval remained a condition for the deal to close – with a previous vote delayed by more than two months due to the COVID-19 pandemic.